Kymera Therapeutics, Inc.

KYMR

Kymera Therapeutics, Inc.

KYMR

Insider Sentiment (TTM):

Last Purchase:2025-12-11Last Sale:2026-06-29Shares Purchased (TTM):2,005,813Shares Sold (TTM):3,321,263

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:84,545,532Shares Outstanding:97,534,269Institutional Ownership Pct.:86.68%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	124	144	357	113	336	90	120	111	68	94	110	81
Available For Sale Securities Debt Securities Curr…	567	507	491	393	330	373	368	439	442	427	265	277
Accounts Receivable Net Current	-	-	-	-	40	-	0	0	0	0	15	-
Contract With Customer Asset Net Current	-	-	-	0	0	20	1	1	2	2	4	4
Prepaid Expense And Other Assets Current	26	27	23	23	23	18	22	17	14	15	12	14
Assets Current	737	677	871	528	728	501	510	569	525	537	405	376
Available For Sale Securities Debt Securities Nonc…	814	895	771	473	298	312	362	361	192	224	61	77
Property Plant And Equipment Net	40	42	43	45	49	49	50	51	52	49	48	36
Operating Lease Right Of Use Asset	41	42	42	43	46	47	47	48	49	49	53	55
Other Assets Noncurrent	7	8	9	7	5	3	2	0	2	2	2	3
Restricted Cash Noncurrent	6	6	6	6	6	6	6	6	6	6	6	6
Assets	1,645	1,669	1,743	1,102	1,131	918	978	1,035	826	868	576	552
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	9	13	4	6	6	10	6	6	7	7	7	5
Accrued Liabilities Current	48	35	42	29	28	23	35	27	24	16	34	26
Contract With Customer Liability Current	0	0	23	23	40	11	14	20	19	23	38	27
Operating Lease Liability Current	12	12	12	12	12	12	12	12	11	9	5	3
Finance Lease Liability Current	-	2	2	2	2	2	2	1	1	1	1	1
Other Liabilities Current	0	1	0	0	0	1	0	1	0	1	1	1
Liabilities Current	71	63	83	72	88	59	68	67	62	56	86	63
Liabilities Noncurrent
Contract With Customer Liability Noncurrent	0	0	11	14	-	-	0	0	3	24	17	16
Operating Lease Liability Noncurrent	64	66	67	68	70	71	72	74	75	76	77	77
Finance Lease Liability Noncurrent	-	1	1	2	2	2	2	2	1	1	1	1
Liabilities	136	129	163	156	160	132	142	142	141	157	181	157
Stockholders Equity
Other Liabilities Noncurrent	-	-	-	-	-	-	0	-	-	-	0	0
Preferred Stock Value	0	0	0	0	0	-	0	-	-	-	-	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	2,713	2,679	2,644	1,924	1,868	1,606	1,592	1,575	1,308	1,292	926	914
Retained Earnings Accumulated Deficit	-1,196	-1,135	-1,066	-979	-897	-820	-755	-684	-621	-579	-531	-516
Accumulated Other Comprehensive Income Loss Net Of…	-7	-4	2	2	0	-0	-1	2	-2	-2	-1	-2
Stockholders Equity	1,509	1,540	1,580	946	971	786	836	893	685	711	395	396
Liabilities And Stockholders Equity	1,645	1,669	1,743	1,102	1,131	918	978	1,035	826	868	576	552
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	-	0	-	-	-	-	-
Preferred Stock Shares Authorized	10	10	10	10	10	-	10	-	-	-	-	-
Preferred Stock Shares Issued	0	0	0	0	0	-	0	-	-	-	-	-
Preferred Stock Shares Outstanding	0	0	0	0	0	-	0	-	-	-	-	-
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	83	82	81	72	71	65	65	65	62	61	56	55
Shares Outstanding	83	82	81	72	71	65	65	65	62	61	56	55

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-2.69%	11.55%	42.80%	-	-	-	-	-	-	-	-	-
2025	-1.43%	46.72%	52.28%	15.47%	53.66%	64.12%	13.30%	35.74%	16.73%	-18.02%	-7.70%	-13.49%
2024	-6.20%	-11.87%	18.73%	19.97%	20.79%	19.05%	-2.58%	-11.93%	-12.04%	7.57%	-14.15%	0.00%
2023	-	-	-	-	-	-	65.15%	112.75%	127.57%	0.22%	-12.13%	-6.40%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	10.34	10.81	10.47	7.38	8.32	8.49	7.53	8.55	8.45	9.57	4.73	5.95
Quick Ratio	9.97	10.39	10.19	7.07	8.06	8.19	7.21	8.29	8.23	9.31	4.59	5.72
Working Capital	665.94M	614.79M	788.00M	456.72M	640.79M	441.96M	442.50M	502.18M	463.26M	481.12M	319.63M	312.53M
Leverage & Debt
Debt to Equity	0.09	0.08	0.10	0.16	0.16	0.17	0.17	0.16	0.21	0.22	0.46	0.40
Debt Ratio	0.08	0.08	0.09	0.14	0.14	0.14	0.15	0.14	0.17	0.18	0.31	0.28
Efficiency & Turnover
Asset Turnover TTM	0.08	0.04	0.03	0.04	0.05	0.07	0.06	0.11	0.13	0.11	0.13	0.08
Days Sales Outstanding TTM	-	-	-	-	326.54	-	-	-	-	-	69.66	-
Receivables Turnover TTM	-	-	-	-	1.12	-	-	-	-	-	5.24	-
Per Share Metrics
Diluted EPS TTM	-3.05	-3.23	-3.69	-3.38	-3.42	-3.01	-2.98	-2.20	-2.16	-2.18	-2.52	-2.87
Free Cash Flow Per Share TTM	-2.33	-2.50	-2.77	-1.72	-2.16	-3.00	-2.77	-1.95	-1.89	-1.93	-2.35	-2.97
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-333.50%	-697.66%	-891.07%	-759.73%	-697.51%	-472.50%	-555.82%	-228.63%	-209.57%	-224.19%	-210.62%	-394.59%
Net Profit Margin TTM	-285.33%	-611.94%	-794.04%	-674.81%	-616.03%	-409.07%	-475.57%	-191.26%	-178.27%	-194.67%	-186.99%	-357.47%
Growth Metrics
Net Revenue Growth (1Y)	134.84%	-12.58%	-16.70%	-50.05%	-49.51%	-25.85%	-40.11%	86.92%	71.38%	70.16%	67.84%	1.92%
Net Income Growth (1Y)	8.77%	30.77%	39.08%	76.22%	74.49%	55.82%	52.32%	0.01%	0.16%	-2.80%	-5.07%	8.85%
EPS Growth (1Y)	-10.87%	7.46%	23.53%	53.66%	58.46%	37.59%	18.47%	-23.25%	-20.03%	-20.09%	-12.28%	1.61%
Valuation Metrics
P/E TTM	-37.58	-25.79	-21.12	-16.74	-12.75	-9.11	-13.49	-21.51	-13.82	-18.40	-10.11	-4.85
P/B TTM	7.46	5.28	4.16	5.22	3.61	2.79	3.61	4.04	3.18	4.00	3.76	2.05
P/S TTM	107.22	157.81	167.66	112.98	78.52	37.25	64.14	41.15	24.63	35.82	18.91	17.33
Market Cap	11.26B	8.12B	6.57B	4.94B	3.51B	2.19B	3.02B	3.60B	2.18B	2.84B	1.49B	812.06M
Enterprise Value	11.13B	7.98B	6.22B	4.83B	3.18B	2.11B	2.90B	3.50B	2.12B	2.75B	1.38B	732.67M
Calculated Values
Free Cash Flow TTM	-228.30M	-244.00M	-234.34M	-150.59M	-173.68M	-240.34M	-207.72M	-148.58M	-137.92M	-136.32M	-137.31M	-173.64M
Net Debt	-124.48M	-141.24M	-353.73M	-109.26M	-331.70M	-86.50M	-116.51M	-107.63M	-65.68M	-91.22M	-107.39M	-79.40M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-29Sale

Owner: Booth, Bruce

Title: -

Shares: 31,283

Price/Share: $109.98

Value: $3,440,504.34

Shares Owned: 461,794

Relationship: Director

Ownership: Indirect

2026-06-26Sale

Owner: Biotechnology, Value Fund…

Title: -

Shares: 1,578,800

Price/Share: $106.50

Value: $168,142,200.00

Shares Owned: 240,123

Relationship: Director,Other

Ownership: Direct

2026-06-26Sale

Owner: Booth, Bruce

Title: -

Shares: 467,878

Price/Share: $113.18

Value: $52,954,432.04

Shares Owned: 472,267

Relationship: Director

Ownership: Indirect

2026-06-25Sale

Owner: Goodman, Noah

Title: Chief Business Officer

Shares: 5,000

Price/Share: $114.00

Value: $570,000.00

Shares Owned: 50,195

Relationship: Officer

Ownership: Direct

2026-06-25Sale

Owner: Booth, Bruce

Title: -

Shares: 285,684

Price/Share: $124.62

Value: $35,601,940.08

Shares Owned: 529,718

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Booth, Bruce	Director	-	Indirect	Sale	31,283	109.98	$3,440,504.34	461,794	4
2026-06-26	Biotechnology, Value Fund…	Director,Other	-	Direct	Sale	1,578,800	106.50	$168,142,200.00	240,123	4
2026-06-26	Booth, Bruce	Director	-	Indirect	Sale	467,878	113.18	$52,954,432.04	472,267	4
2026-06-25	Goodman, Noah	Officer	Chief Business Officer	Direct	Sale	5,000	114.00	$570,000.00	50,195	4
2026-06-25	Booth, Bruce	Director	-	Indirect	Sale	285,684	124.62	$35,601,940.08	529,718	4
2026-06-24	Booth, Bruce	Director	-	Indirect	Sale	134,720	100.78	$13,577,081.60	597,047	4
2026-06-22	Booth, Bruce	Director	-	Indirect	Sale	31,798	103.90	$3,303,812.20	613,762	4
2026-06-22	Goodman, Noah	Officer	Chief Business Officer	Direct	Sale	2,500	99.00	$247,500.00	50,195	4
2026-06-18	Booth, Bruce	Director	-	Indirect	Sale	115,056	91.50	$10,527,624.00	647,914	4
2026-05-27	Chadwick, Jeremy G	Officer	Chief Operating Officer	Direct	Sale	4,279	81.79	$349,979.41	44,018	4
2026-05-11	Ridloff, Elena	Director	-	Direct	Sale	3,000	87.00	$261,000.00	0	4
2026-04-29	Mainolfi, Nello	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	81.63	$2,448,900.00	666,195	4
2026-04-22	Booth, Bruce	Director	-	Direct	Sale	5,900	89.96	$530,764.00	0	4
2026-04-22	Chadwick, Jeremy G	Officer	Chief Operating Officer	Direct	Sale	300	90.00	$27,000.00	61,202	4
2026-04-15	Chadwick, Jeremy G	Officer	Chief Operating Officer	Direct	Sale	1,300	90.00	$117,000.00	61,202	4
2026-04-15	Booth, Bruce	Director	-	Direct	Sale	2,200	89.95	$197,890.00	0	4
2026-04-14	Goodman, Noah	Officer	Chief Business Officer	Direct	Sale	1,347	90.00	$121,230.00	50,195	4
2026-04-10	Goodman, Noah	Officer	Chief Business Officer	Direct	Sale	2,000	87.35	$174,700.00	51,542	4
2026-04-01	Ridloff, Elena	Director	-	Direct	Sale	4,600	85.62	$393,852.00	0	4
2026-03-31	Chadwick, Jeremy G	Officer	Chief Operating Officer	Direct	Sale	7,600	85.38	$648,888.00	61,202	4
2026-03-25	Chadwick, Jeremy G	Officer	Chief Operating Officer	Direct	Sale	24,727	80.26	$1,984,589.02	61,202	4
2026-03-20	Esposito, Pamela	Director	-	Direct	Sale	2,500	78.96	$197,400.00	0	4
2026-03-11	Chadwick, Jeremy G	Officer	Chief Operating Officer	Direct	Sale	25,758	82.98	$2,137,398.84	68,052	4
2026-03-04	Chadwick, Jeremy G	Officer	Chief Operating Officer	Direct	Sale	3,919	85.36	$334,525.84	73,810	4
2026-03-04	Jacobs, Bruce N.	Officer	Chief Financial Officer	Direct	Sale	4,895	85.36	$417,837.20	232,588	4
2026-03-04	Gollob, Jared	Officer	Chief Medical Officer	Direct	Sale	4,895	85.36	$417,837.20	117,134	4
2026-03-02	Booth, Bruce	Director	-	Indirect	Sale	81,866	90.13	$7,378,582.58	675,341	4
2026-02-25	Mainolfi, Nello	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	91.65	$2,749,500.00	666,195	4
2026-02-20	Esposito, Pamela	Director	-	Direct	Sale	2,500	87.58	$218,950.00	0	4
2026-01-20	Esposito, Pamela	Director	-	Direct	Sale	5,500	67.73	$372,515.00	0	4
2025-12-31	Mainolfi, Nello	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	78.24	$2,347,200.00	663,077	4
2025-12-17	Esposito, Pamela	Director	-	Direct	Sale	27,563	82.86	$2,283,870.18	0	4
2025-12-12	Booth, Bruce	Director	-	Indirect	Sale	678	91.04	$61,725.12	685,393	4
2025-12-11	Baker, Felix, Baker Julia…	Director,TenPercentOwner	-	Indirect	Purchase	2,005,813	86.00	$172,499,918.00	7,955,916	4
2025-12-08	Albers, Jeffrey W.	Director	-	Direct	Sale	5,000	89.81	$449,050.00	0	4
2025-12-08	Mainolfi, Nello	Director,Officer	Chief Executive Officer	Direct	Sale	100,000	89.17	$8,917,000.00	660,482	4
2025-12-08	Gollob, Jared	Officer	Chief Medical Officer	Direct	Sale	49,307	89.76	$4,425,796.32	109,992	4
2025-10-29	Mainolfi, Nello	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	60.73	$1,821,900.00	660,482	4
2025-10-15	Gollob, Jared	Officer	Chief Medical Officer	Direct	Sale	59,576	61.92	$3,688,945.92	109,992	4
2025-10-13	Albers, Jeffrey W.	Director	-	Direct	Sale	5,000	59.19	$295,950.00	0	4
2025-10-13	Gollob, Jared	Officer	Chief Medical Officer	Direct	Sale	3,114	60.00	$186,840.00	118,359	4
2025-09-17	Jacobs, Bruce N.	Officer	Chief Financial Officer	Direct	Sale	79,220	50.00	$3,961,000.00	227,409	4
2025-09-16	Mainolfi, Nello	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	49.00	$1,470,000.00	660,482	4
2025-06-30	Biotechnology, Value Trad…	Director,Other	-	Direct	Purchase	317,167	44.00	$13,955,348.00	2,798,795	4
2025-06-30	Baker, Bros. Advisors (Gp…	Director	-	Indirect	Purchase	655,500	44.00	$28,842,000.00	6,117,295	4
2025-06-11	Ridloff, Elena	Director	-	Direct	Sale	4,500	50.00	$225,000.00	0	4
2025-06-03	Albers, Jeffrey W.	Director	-	Direct	Sale	6,349	49.00	$311,101.00	0	4
2025-06-03	Ridloff, Elena	Director	-	Direct	Sale	12,000	46.25	$555,000.00	0	4
2025-06-03	Esposito, Pamela	Director	-	Direct	Sale	5,000	49.04	$245,200.00	0	4
2025-06-03	Mainolfi, Nello	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	49.00	$1,470,000.00	660,482	4
2025-05-23	Chadwick, Jeremy G	Officer	Chief Operating Officer	Direct	Sale	2,575	29.30	$75,447.50	66,420	4
2025-03-03	Chadwick, Jeremy G	Officer	Chief Operating Officer	Direct	Sale	1,383	30.66	$42,402.78	67,800	4
2025-03-03	Chiniara, Ellen	Officer	Chief Legal Officer	Direct	Sale	2,241	30.66	$68,709.06	80,085	4
2025-03-03	Gollob, Jared	Officer	Chief Medical Officer	Direct	Sale	5,740	30.66	$175,988.40	120,000	4
2025-03-03	Jacobs, Bruce N.	Officer	Chief Financial Officer	Direct	Sale	7,035	30.66	$215,693.10	201,886	4
2025-01-06	Chiniara, Ellen	Officer	Chief Legal Officer	Direct	Sale	3,129	41.75	$130,635.75	54,826	4
2024-12-02	Esposito, Pamela	Director	-	Direct	Sale	2,500	49.00	$122,500.00	0	4
2024-09-17	Esposito, Pamela	Director	-	Direct	Sale	13,500	48.25	$651,375.00	0	4
2024-08-26	Albers, Jeffrey W.	Director	-	Direct	Sale	5,000	49.10	$245,500.00	0	4
2024-08-20	667,, L.P., Baker Brother…	Director	-	Indirect	Purchase	1	46.41	$46.41	5,516,986	4
2024-07-16	Gollob, Jared	Officer	Chief Medical Officer	Direct	Sale	23,145	45.84	$1,060,966.80	95,470	4
2024-07-09	Booth, Bruce	Director	-	Indirect	Sale	453,960	37.42	$16,987,183.20	723,246	4
2024-06-13	Booth, Bruce	Director	-	Indirect	Sale	10,200	34.98	$356,796.00	802,022	4
2024-06-07	Horobin, Joanna	Director	-	Direct	Sale	8,500	32.88	$279,480.00	0	4
2024-05-23	Chadwick, Jeremy G	Officer	Chief Operating Officer	Direct	Sale	2,575	34.99	$90,099.25	44,183	4
2024-03-15	Booth, Bruce	Director	-	Indirect	Sale	71,764	40.39	$2,898,547.96	806,697	4
2024-03-13	Atlas, Venture Associates…	TenPercentOwner	-	Direct	Sale	115,090	42.52	$4,893,626.80	4,676,075	4
2024-03-13	Booth, Bruce	Director	-	Indirect	Sale	139,255	42.52	$5,921,122.60	828,830	4
2024-03-04	Gollob, Jared	Officer	Chief Medical Officer	Direct	Sale	3,344	42.35	$141,618.40	95,740	4
2024-03-04	Jacobs, Bruce N.	Officer	Chief Financial Officer	Direct	Sale	3,934	42.35	$166,604.90	142,351	4
2024-02-27	Gollob, Jared	Officer	Chief Medical Officer	Direct	Sale	400	45.00	$18,000.00	74,709	4
2024-02-21	Albers, Jeffrey W.	Director	-	Direct	Sale	4,385	39.05	$171,234.25	0	4
2024-02-09	Gollob, Jared	Officer	Chief Medical Officer	Direct	Sale	46,137	35.74	$1,648,936.38	74,709	4
2024-01-23	Albers, Jeffrey W.	Director	-	Direct	Sale	10,000	30.05	$300,500.00	0	4
2024-01-04	Chiniara, Ellen	Officer	Chief Legal Officer	Direct	Sale	3,295	22.58	$74,401.10	34,205	4
2023-11-03	Bvf, Ii Gp Llc, Bvf I Gp …	Director,Other	-	Direct	Purchase	197,699	14.07	$2,781,624.93	2,656,191	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

86.68%

Inst. Shares: 84,545,532

Shares Outstanding: 97,534,269

2025-12-31

98.04%

Inst. Shares: 82,831,028

Shares Outstanding: 84,490,585

2025-09-30

85.94%

Inst. Shares: 75,024,566

Shares Outstanding: 87,300,286

2025-06-30

88.75%

Inst. Shares: 71,395,486

Shares Outstanding: 80,449,405

2025-03-31

82.12%

Inst. Shares: 65,816,129

Shares Outstanding: 80,146,531

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	84,545,532	97,534,269	86.68%
2025-12-31	82,831,028	84,490,585	98.04%
2025-09-30	75,024,566	87,300,286	85.94%
2025-06-30	71,395,486	80,449,405	88.75%
2025-03-31	65,816,129	80,146,531	82.12%
2024-12-31	64,079,711	75,043,991	85.39%
2024-09-30	61,908,763	76,125,975	81.32%
2024-06-30	60,690,450	73,059,398	83.07%
2024-03-31	60,183,239	70,770,320	85.04%
2023-12-31	50,460,091	58,365,499	86.46%
2023-09-30	48,006,776	58,421,859	82.17%
2023-06-30	48,873,652	58,326,963	83.79%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Kymera Therapeutics, Inc. (KYMR) — SEC Financial Statements & Analysis

Kymera Therapeutics, Inc. (KYMR) is a biological products, (no diagnostic substances) company, incorporated in DE. Kymera Therapeutics, Inc. trades on Nasdaq as: KYMR. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Kymera Therapeutics, Inc. reported a 134.84% year-over-year revenue growth, a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of 107.22x (TTM), a Price-to-Book (P/B) ratio of 7.46x (TTM), at a market cap of $11.26B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 134.84%
Debt To Equity: 0.09x
P/S TTM: 107.22x
P/B TTM: 7.46x
Market Cap: $11.26B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Kymera Therapeutics, Inc. in?

Kymera Therapeutics, Inc. (KYMR) operates in the Biological Products, (No Diagnostic Substances) industry.

What is KYMR's market cap?

Kymera Therapeutics, Inc. (KYMR) has a market capitalization of $11.26B as of 2026-06-30.

What exchange does KYMR trade on?

Kymera Therapeutics, Inc. (KYMR) trades on the Nasdaq.

Where is Kymera Therapeutics, Inc. incorporated?

Kymera Therapeutics, Inc. is incorporated in DE.